Segment Information

6 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment Information

(10) Segment Information

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

Human Health - includes finished dosage form generic drugs and nutraceutical products.

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

Six months Ended December 31, 2017 and 2016:

	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated Totals
2017
Net sales	$	209,481	$	70,205	$	76,798	$	-		$	356,484
Gross profit		47,545		10,221		16,187		-			73,953
Income (loss) before income taxes		7,314		2,808		7,422		(15,905	)		1,639
2016
Net sales	$	101,870	$	77,432	$	74,268	$	-		$	253,570
Gross profit		31,124		12,612		17,908		-			61,644
Income (loss) before income taxes		8,905		4,263		8,565		(15,887	)		5,846

Three months Ended December 31, 2017 and 2016:

	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated Totals
2017
Net sales	$	103,466	$	33,629	$	34,134	$	-		$	171,229
Gross profit		22,898		4,381		6,691		-			33,970
Income (loss) before income taxes		2,288		577		2,477		(5,841	)		(499	)
2016
Net sales	$	53,981	$	36,816	$	34,755	$	-		$	125,552
Gross profit		16,919		5,658		8,228		-			30,805
Income (loss) before income taxes		4,933		1,196		3,733		(10,796	)		(934	)